

Mexico City, April 1st, 2015

GENOMMA LAB ANNOUNCES EARNINGS PREVIEW FOR THE FIRST QUARTER OF 2015

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) (“Genomma Lab” or “the Company”) announces preliminary results for the first quarter of 2015.

The objective of the information contained in this document is to give an explanation regarding the earnings expected for the first quarter of 2015, in order to improve the understanding and to mitigate the uncertainty of the market before the official announcement of the Company’s quarterly results.

Based on preliminary financial information, the Company expects:

- 1) A consolidated growth in the first quarter of 2015 of approximately 5%, compared to the same period of 2014;
- 2) An EBITDA in line with our guidance.

Highlights:

- Sales in the international markets had a very solid performance, which allowed us to accelerate the new commercial plan of reducing inventories in Mexico at the point of sale.
- The market share results in Mexico, according to monitored information of January and February of 2015 and compared to the same period of 2014, behaved with a slight reduction of market share in OTC and an increase of market share in personal care, due to a better exhibition of our main brands as part of our new commercial strategy.

The combined market share of the categories where we participate has increased and we continue to reduce inventories at the point of sale, given that the *sell-out* outperformed the *sell-in* in Mexico. This will be reflected in a decrease in sales in Mexico in the first quarter of 2015 compared to the same period of 2014. However, consolidated growth of the quarter is in line with our guidance given the strong *sell-out* in our international markets, mainly in the United States.

The Company will be reporting the market share information of both segments (OTC and personal care) in Mexico, as well as the detailed financial information of the first quarter of 2015 on April 29, 2015.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low - cost, highly flexible supply chain operating model.

Contact:

Investor Relations
Tel: +52 (55) 5081 0000 Ext. 5106
E-mail: inversion@genommalab.com

In New York: Grayling USA, Lucía Domville
Tel: +1 (646) 284-9416
E-mail: genommalab@grayling.com

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.